Claims
- 1. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising one or more of the following compounds:
- 2. The pharmaceutical composition of claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 3. The pharmaceutical composition of claim 2, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist
- 4. Use of the pharmaceutical composition of claim 1 in the preparation of a medicament for treatment of a disease condition associated with excess IgE.
- 5. A method for treating or preventing an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of claim 1.
- 6. The method of claim 5 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 7. The method of claim 6, wherein said additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 8. A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of claim 1.
- 9. The method of claim 8 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 10. The method of claim 9, wherein said additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 11. The pharmaceutical composition of claim 1, wherein the compound is from Genus A.
- 12. The pharmaceutical composition of claim 11, wherein the compound is selected from the group consisting of:
- 13. The pharmaceutical composition of claim 1, wherein the compound is from Genus B.
- 14. The pharmaceutical composition of claim 13, wherein the compound is selected from the group consisting of:
- 15. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising one or more of the following compounds:
- 16. A method for treating or preventing an allergic reaction in a mammal comprising administering an IgE-suppressing amount of at least one compound of claim 15
- 17. A method of preparing a compound or salt thereof having the formula:
- 18. A method of preparing a compound or salt thereof having the formula:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part application of pending U.S. application Ser. No. 09/422,304, filed on Oct. 21, 1999, which claims priority to U.S. application Ser. No. 09/316,870, filed on May 21, 1999, now U.S. Pat. No. 6,271,390, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/086,494, filed on May 21, 1998, all herein incorporated by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09422304 |
Oct 1999 |
US |
Child |
10103258 |
Mar 2002 |
US |